A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

Viatris

Status: Completed

Conditions: Prostatic Hyperplasia

Treatments: Drug: Doxazosin mesylate GITS

Study type: Observational

Funder types: Industry

Identifiers

NCT01003886

A0351068

Details and patient eligibility

About

This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.

Full description

This is an open label study. All patients prescribed with Doxazosin GITS can be enrolled in this study.

Enrollment: 989 patients

Sex: Male

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects that will be included must be consistent with the approved label indication of Doxazosin mesylate GITS in the Philippines, which includes adult male diagnosed with BPH, and who are prescribed with Doxazosin mesylate GITS.

Exclusion criteria

• Subjects with condition that are contraindicated with Doxazosin mesylate GITS based on the approved labeling in the Philippines.

Trial design

989 participants in 1 patient group

Open Label

Description:

Adult male diagnosed with BPH and prescribed with Doxazosin mesylate GITS

Treatment:

Drug: Doxazosin mesylate GITS